CoDiagnostics Secures Patent for Co-Dx PCR Testing Platform Amid Reverse Stock Split Announcement

Co-Diagnostics Secures Patent for Innovative PCR Testing Platform

CoDiagnostics, Inc., a leader in molecular diagnostics, achieves a significant milestone with the granting of Australian Patent No. AU2022270084A1 for its state-of-the-art point-of-care testing platform. The patent, awarded by the Australian Patent Office, protects the design and operation of the Co-Dx PCR Pro™ instrument and its accompanying test cups, which facilitate high-quality polymerase chain reaction (PCR) testing outside traditional laboratory environments. This development comes after the patent was filed in May 2022 and granted in June 2023, highlighting Co-Diagnostics’ commitment to expanding its intellectual property portfolio in a rapidly evolving industry.

CEO Dwight Egan emphasizes the importance of this patent in securing global protection for their innovative technology, which is essential for broadening the applications of the Co-Dx PCR platform. The timing of this patent acquisition is particularly strategic, as Australia recently experienced an unprecedented flu season. This context underscores the commercial potential of Co-Diagnostics' testing solutions, including the Co-Dx PCR Flu A/B, COVID, and RSV multiplex test, which is currently undergoing clinical performance testing. Egan's remarks indicate that the patent enhances not only the company’s competitive edge but also its ability to respond to urgent public health challenges.

The Co-Dx PCR platform aims to deliver gold-standard PCR accuracy in a compact and user-friendly device, ideal for decentralized testing environments. Utilizing Co-Diagnostics' proprietary Co-Primers® technology, the platform is designed to provide rapid and sensitive molecular diagnostics for a wide range of infectious diseases. However, it is essential to note that the Co-Dx PCR platform and its associated tests are subject to review by the FDA and other regulatory bodies, meaning they are not yet available for commercial sale. Co-Diagnostics remains focused on making accurate PCR testing accessible in critical areas where it is most needed.

In addition to the patent news, Co-Diagnostics also announces a reverse stock split of its common stock at a 1-for-30 ratio, effective January 2, 2026. This decision follows approval from stockholders and aims to help the company meet the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The reverse stock split will adjust the shares available under the company’s equity incentive plans, ensuring compliance with regulatory standards.

Overall, Co-Diagnostics continues to position itself as a frontrunner in the molecular diagnostics sector, with its recent patent acquisition and strategic decisions reinforcing its commitment to innovation and public health.